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Abstract
Susceptibility to common cancers is multigenic resulting from low-to-high penetrance predisposition-factors and
environmental exposure. Genomic studies suggest germline homozygosity as a novel low-penetrance factor contributing to
common cancers. We hypothesized that long homozygous regions (tracts-of-homozygosity [TOH]) harbor tobacco-
dependent and independent lung-cancer predisposition (or protection) genes. We performed in silico genome-wide SNP-
array-based analysis of lung-cancer patients of European-ancestry from the PLCO screening-trial cohort to identify TOH
regions amongst 788 cancer-cases and 830 ancestry-matched controls. Association analyses was then performed between
presence of lung cancer and common(c)TOHs (operationally defined as 10 or more subjects sharing $100 identical
homozygous calls), aTOHs (allelically-matched groups within a cTOH), demographics and tobacco-exposure. Finally,
integration of significant c/aTOH with transcriptome was performed to functionally-map lung-cancer risk-genes. After
controlling for demographics and smoking, we identified 7 cTOHs and 5 aTOHs associated with lung cancer (adjusted
p,0.01). Three cTOHs were over-represented in cases over controls (OR=1.75–2.06, p=0.007–0.001), whereas 4 were
under-represented (OR=0.28–0.69, p=0.006–0.001). Interaction between smoking status and cTOH3/aTOH2 (2p16.3–
2p16.1) was observed (adjusted p,0.03). The remaining significant aTOHs have ORs 0.23–0.50 (p=0.004–0.006) and 2.95–
3.97 (p=0.008–0.001). After integrating significant cTOH/aTOHs with publicly-available lung-cancer transcriptome datasets
followed by filtering based on lung cancer and its relevant pathways revealed 9 putative predisposing genes (p,0.0001). In
conclusion, differentially-distributed cTOH/aTOH genomic variants between cases and controls harbor sets of plausible
differentially-expressed genes accounting for the complexity of lung-cancer predisposition.
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Introduction
There are two main histologic groupings in lung cancer, small
cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
The latter includes adenocarcinoma (AC) and squamous cell
carcinoma (SCC), along with less common subtypes. It has been
widely accepted that an average of 5–10% of all malignancies are
caused by high penetrance predisposition genes [1–3]. For
example, there are 10 high penetrance genes, including BRCA1/
2 and PTEN, accounting for ,10% of all breast cancers [3]. While
aerodigestive tract cancers are believed to be a rare part of the
neoplastic spectrum of BRCA2, no other high penetrance lung-
cancer-predisposition gene has been identified, and until recently,
lung cancer has been attributed almost entirely to environmental
exposure, chiefly tobacco. In the last few years, however, it has
become obvious that a greater, but variable, proportion of all
malignancies have a genomic component, conferring weaker
predisposition (low penetrance). Eg, a genome-wide association
study (GWAS) demonstrated specific single nucleotide polymor-
phims (SNPs) associated with risk of AC in smokers and never-
smokers [4]. To date, NSCLC, especially AC-associated genomic-
loci have been identified in 15q25, 5p15, and 6p21 [5–10].
Analysis of the effect of smoking on lung-cancer risk showed that
smoking does not entirely explain the risk of developing lung
cancers and that residual genomic-factors interacting with smoking
are likely [4]. Genomic variants, such as the associated SNPs,
cannot fully explain the heterogeneity associated with the
histologic subtypes either [11,12]. The evidence to date suggests
the need to find other types of genomic variation that can explain
the relatively large remaining risk associated with lung carcinomas.
In animal husbandry and animal-model experimentation, in-
breeding which results in increasing homozygous loci is well
recognized to result in increased incidence of various disorders,
including increasing tumor incidence [13]. In humans, germline
homozygosity as a genomic factor associated with disease-risk is a
relatively recent concept. Eg, germline homozygosity, a type of
genomic variation, has been shown to be associated with an
increased risk of human cervical cancer. Identification of
homozygous loci as risk factors may help target heightened
cervical screening for high-risk women [14–18]. Relatedly, a
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of germline homozygosity in a series of unrelated white individuals
with invasive breast carcinomas, prostate carcinomas and head
neck squamous cell caricinomas by genome-wide microsatellite
genotyping [19]. This association was validated in a study of AC
cases and matched-controls that were genotyped with denser SNP-
based arrays (Illumina HumanHap550v3_B array), thus support-
ing the high likelihood of identifying homozygous genotypes that
are associated with a broad variety of common solid tumors [19].
This study observed that homozygosity from both microsatallite-
and SNP-based analyses showed specific, shared loci of homozy-
gosity for all the three tumor types studied. In addition, there were
also highly homozygous loci that are specific to each of the tumor
types. Independently, Bacolod and colleagues [20] found that long
tracts of homozygosity (TOH), operationally defined as spanning
at least 4 Mb, were over-represented in colorectal cancer patients
over controls.
Here, we hypothesized that germline regional-homozygosity
involving specific chromosomal loci is a novel genomic factor
contributing to low- to-moderate penetrance predisposition to (or
protection from) lung cancer. Instead of identifying single genes,
our hypothesis takes into account subsets of genes within these
regions, which are differentially expressed to lend complex
predisposition to lung cancer. We sought to address this hypothesis
by systematically integrating data from differentially represented
TOH regions with genome-wide expression data to localize
regional lung-cancer predisposition loci.
Methods
Acquisition of Genotype Data from dbGAP
Genotypes were obtained from the Prostate, Lung, Colorectal
and Ovarian cancer screening trial (PLCO) where the lung cohort
was prospectively screened with chest X-rays [21]. Subjects were
all self-identified as white, and comprise ancestry-matched cases
and controls [21] based on principle-component analyses using
both SNPs unlinked to lung cancer and their ancestry-informed
SNP’s, as described by Patterson et al [22]. Consistently, the
CEPH (Centre d’Etude du Polymorphisme Humain) from Utah
(CEU) HapMap controls cluster with this population, re-
confirming northern and western European origin [23].
We followed the standard quality control (QC) procedure used
in the original study [4]. Samples were screened and selected
only if they had a minimum 95% successful genotype call rate.
SNPs with minor allele frequencies (MAF) ,5%, departures
from Hardy-Weinberg equilibrium (at p,0.01) and $5%
missingness per SNP, were excluded from further analyses.
After QC filtering, we had 1618 subjects (788 cases and 830
ancestry matched controls) with mean age categories of 1.63 (5
categories defined in Table S1), comprising 967 males and 651
females, including 156 nonsmokers, 703 previous smokers and
759 current smokers (Table S1); and an average 526,826
(514,355 autosomal) SNPs (93.8%)/subject. Table S1 shows
the association analysis based on a logistic model with age,
gender and smoking status (never smoked, previous smoking and
current smoking) as covariates after excluding the potential
genetic effects. It is important to note that the proportion of
current smokers was about half the rate of active smokers in the
US general population. It was noted that compliance was the
lowest in the current smokers whereas the previous smokers were
the most compliant.
Quantifying Tracts of Homozygosity and Comparing
Frequencies in Cancer Cases and Controls
Identifying tracts of homozygosity (TOH) and common
TOH (cTOH) region. We extended the module of Runs of
Homozygosity in the GoldenHelix software [24] to identify TOHs
[an in-house software (Zhang et al, unpublished)]. Next, data from
all subjects were examined to determine whether a minimum
number of individuals share a TOH call at a given position. To
identify statistical differences between TOHs within a case-control
design, we only retained those TOHs in which 10 or more subjects
share 100 identical homozygous calls, which we operationally
define as a common TOH (cTOH). There are 333,861 SNPs with
10 or more TOH calls across the entire series, representing 65% of
the original pool of SNPs.
Detection of cTOHs associated with lung cancer. We
then pursued testing for association between cTOH and lung-
cancer cases. By considering each cTOH as a genomic variant, a
genome-wide case-control analysis was conducted for each
cTOH, where a cTOH was viewed as a binary variable based
on the presence or absence of a cTOH. Using each TOH
(containing multiple SNPs that are in linkage disequilibrium) as a
variable will considerably reduce the number of tests to be
performed and boost the power of the association analysis. The
traditional single SNP-association studies require at least 610 000
(up to 3 million if more SNPs are used) tests if a traditional
GWAS was done. A logistic model was fitted for each cTOH by
considering disease status as the outcome and the cTOH as the
predictor. Other covariates included in the model were age, sex
and smoking status. P-values were obtained by Wald tests and
OR (95% CI) were calculated through coefficient estimates of the
fitted logistic model. To detect interactions between cTOH and
smoking status, and cTOH and age, a logistic model with two
extra interaction terms was fitted for each cTOH. The P-value of
interaction was obtained by F-test. To minimize chances of false
positive findings, cTOHs are considered statistically significant if
their p,0.01 [24]. Furthermore, the q-value approach [25], that
is based on the concept of the false discovery rate, was used as an
exploratory guide for which the variants called can be
investigated further.
Investigating allelically-matched groupings within a
cTOH (aTOH). As noted above, a cTOH is operationally
defined by a minimum number of loci that are homozygous and
minimum number of subjects sharing the cTOH, but not
qualitative matching of nucleotides. Within the cTOH, TOH
segments were then compared pair-wise and an allelic match is
declared if at least 0.95 of jointly non-missing, jointly homozygous
sites are identical. These allelic matching groups of TOHs within a
cTOH are termed ‘allelic’TOH (aTOH). The characterization
and scanning of these aTOHs was performed using our
customized software cag-TOH (unpublished software), similar to
the allelic-matching procedure in PLINK [26].
Detection of aTOHs associated with lung cancer
cases. The aTOH as genomic variant was then used for
association analysis within a case-control framework. To retain the
power of the statistical analysis, we only focused on the aTOHs
which are present in at least 5 cases and 5 controls. For each
aTOH, we applied a logistic model with disease status as the
outcome and aTOH as a predictor with age, sex and smoking
status as covariates. Similar to cTOH above, the aTOHs with
p,0.01 by Wald-test are declared significantly associated with
lung cancer. We also applied the q-value approach [25].
Tracts of Homozygosity and Lung Cancer Risk
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Regions with Publicly Available Expression Array Dataset
Data were obtained from a publicly available [27] gene-
expression dataset of 107 fresh frozen tissue samples of AC (58
tumor and 49 non-tumor tissues from 20 never smokers, 26
former smokers, and 28 current smokers) downloaded from the
Gene Expression Omnibus (GSE10072), from the Environment
And Genetics in Lung cancer Etiology (EAGLE) study (http://
dceg.cancer.gov/eagle). The criteria used to select this particular
array dataset provide not only minimal bias, but physiologically
relevant data. We followed the universal standard that specific
selection criteria and QC’s are in place before using publicly
available datasets (e.g. expression array) for cross-platform
integration purposes. Therefore, we ensured that the lung
cancers in the expression array datasets belong to patients who
are similar to those patients who were genotyped and subjected to
TOH analysis. For example, patients utilized in both expression
array and TOH analysis represent two different subsets of one
much larger study cohort. This by itself is a major strength of this
cross platform integration process because patients in the two
datasets were subjected to the same inclusion/selection criteria;
these individuals have been exposed to similar environmental or
treatment conditions; most importantly, ancestral background of
the ‘‘expression array dataset’’ patients were similar to those who
were genotyped for TOH analysis; and the patients are of the
same age ranges, i.e. 55–60 yrs. After QC, we normalized the
expression profiles of the samples using the Robust Multichip
Average (RMA) method, similar to how the same expression
array data were originally processed [28]. The raw probes are
mapped to their corresponding genes, and multiple probes
corresponding to the same gene were averaged. The significant
cTOH regions were first extended 250 kb in each direction, and
genes within these regions were identified (259 genes). The
number of genes included in the region increases linearly as the
flanking regions are extended, but is also dependent on the region
being interrogated (i.e., if a gene rich or gene poor region). If it
returned .1000 genes (which we did not observe in our analyses
here), we would have simply used LD to capture the block of
cTOH or aTOH. The microarray expression profiles of 153 of
the 259 cTOH-genes were found on the expression array.
Subsequently, we evaluated on an a priori basis differences in
expression profiles of these 153 genes using individual univariate
logistic regression with Bonferroni correction applied for
statistical significance calculations (data not shown). Expression
profiles of the significant genes from univariate analysis (p,0.01)
and within the +/2250 kb region of c/aTOH region were
subjected to unsupervised hierarchical clustering [29] using
MatlabH.
Prioritization of Candidate Genes
After integrating significant c/aTOH regions with the expres-
sion array dataset, we determined the risk associated with
differential expression of genes with c/aTOHs stratified by
smoking status. Genes that showed differential expression profiles
significant at p,0.0001 in the ever- and never-smoking strata were
then subjected to a text mining approach to help filter from
relevant information generated from genomic, transcriptomic, and
proteomic investigations available in the PubMed literature
database. Consequently, this information was used to identify
relationship networks between the genes, their transcripts, their
proteins and other lung cancer-relevant biological processes or
pathways [30–32].
Results
Identification of Specific Common Tracts of
Homozygosity (cTOH) in Individuals with Lung Cancer in
the PLCO Cohort
To address our central hypothesis that specific germline TOH is
either over- or under-represented in lung-cancer cases over
ancestry-matched controls, we initially screened for TOH regions
in the PLCO-dataset (schema in Figure 1). We found a total of
91,460 TOHs across all samples with 44,725 TOHs in cases and
46,735 TOHs in controls. Average length of TOHs was 886 kb
(median=677.4 kb, 1
st quartile=484.8 kb, 3
rd quartile=956.3 kb)
and average number of SNPs within each TOH 141.4 (median 121,
1
st quartile108, 3
rd quartile=145). A total of 890 such cTOHs were
identified across the genome, ranging in size 141.6–3421 kb
(mean=2144 kb, SD=3115.6 kb, median=1064 kb, 1
st quartile
623.9 kb, 3
rd quartile 2144 kb) and SNP-count of 100–413
(mean=375, SD=418, median=215).
By considering each cTOH as a genomic variant, we performed
a case-control analysis adjusting for the effects of age, sex and
smoking status. Seven cTOH regions were found to be
significantly differentially represented between LC cases and
controls based on p,0.01 (Table 1, Figure 2 A and Table S2)
[38 cTOH regions were found at p,0.05 (data not shown)]. Three
cTOH regions, cTOH2, 4 and 7 (within 1p12, 3p24.2–3p24.1 and
9p22.3, respectively), have odds ratios (OR)=1.75–2.06
(p=0.007–0.001), showing over-representation of these 3 cTOHs
in lung-cancer cases over controls (Table 1 Table S2, and
Figures 3C and 3D). The remaining four cTOH regions, cTOH1,
3, 5 and 6 (1p13.2, 2p16.3–2p16.1, 5p15.31 and 6p22.3–22.2)
have OR=0.28–0.69 (p=0.006–0.001), showing that these
cTOH’s were under-represented in cases compared to controls
(Table 1, Table S2, and Figures 3A and 3B).
Interestingly, interaction between smoking status and cTOH3
(rs733726, rs4672095 [2p16.3–2p16.1]; Table 1) was observed
(p,0.03, Table S3). While age-, sex- and smoking-status-adjusted
OR for cTOH 3 is 0.69 (Table 1, Figure 2 A), cTOH3 is 2-fold
(OR=1.8) over-represented in non-smoking cases over non-
smoking controls, whereas cTOH3 is significantly under-repre-
sented in ever-smoking cases over ever-smoking controls [OR 0.78
(previous smokers) and 0.34 (current smokers), respectively,
p=0.009–0.026] (Table S3 B).
Identification of Allelically-Matching Groups (aTOH)
within cTOHs in Lung-Cancer Cases and Controls
The aTOHs may provide genetic background or ancestry-
related information, hence a biological meaningful association
with the lung-cancer phenotype. The number of aTOHs in each
cTOH ranges from 1 to 111. We conducted an independent (of
cTOHs identified) case-control analysis followed by adjusting for
the effects of age, sex and smoking status on the lung-cancer
phenotype. In this manner, we identified 5 aTOHs (within
2p16.3–2p16.1, 3p25.3, 5q11.2–12.1, 7q21.11 and 13q31.1–31.3)
that are significantly differentially represented between cases and
controls (based on p,0.01; Table 2). Notably, only aTOH1 with
OR of 0.5 (Table 2), was derived from parent cTOH3 (2p16.3–
16.1) where both cTOH3 and aTOH1 are significantly under-
represented in lung-cancer cases compared to controls (OR=0.69
and 0.5, p=0.001 and 0.005, respectively; Figure 2, Tables 1 and
2). The remaining aTOH regions, aTOH2, 3, 4 and 5 (within
3p25.3, 5q11.2–12.1, 7q21.11 and 13q31.1–31.3, respectively)
have OR=3.97, 0.23, 2.95 and 0.39, respectively (p=0.001–
0.008; Table 2).
Tracts of Homozygosity and Lung Cancer Risk
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Significant cTOH and aTOH Regions with Global
Transcriptome Datasets
We next turned our attention to look for biologically plausible
genes, i.e., one or a subset of all genes, located within and in
proximity (+/2250 kb) to significant c/aTOH’s and that may be
germane to lung cancer risk. To fine map the TOHs containing
lung-cancer-related genes and to functionally validate our genomic
data, we integrated our significant TOH regions with gene
expression data derived from lung cancer patients in the EAGLE
study [27] (Figure 1). This dataset was derived from a population
of European ancestry (selection criteria described in the Methods
section) and also served as our functional validation series. We
were able to filter out genes within the significant c/aTOH regions
to 46 genes based on differential expression in univariate analysis
alone (Figures 1 and 4). With further risk analyses and integration
with known organ-specific function and signaling pathway roles,
we ended up with a final shortlist of 9 most-plausible lung cancer-
Figure 1. Study schema for the identification and functional genomic validation of significant cTOH and aTOH regions that are
over- or under-represented in lung cancer cases. The schema represents the framework used to identify and subsequently integrate significant
cTOHs and aTOHs (from the PLCO lung cancer screening trial) with global transcriptome datasets comparing lung cancers to normal lungs (from the
EAGLE lung cancer screening trial). Multiple differentially expressed genes within the cTOHs and aTOHs had their candidacy prioritized initially based
on statistical significance followed by biological plausibility (eg, relevant mouse models, reported to be somatically altered in sporadic lung cancers,
relevant signaling pathways, etc) to finally obtain 9 ‘‘most plausible’’ candidate genes and one candidate genomic region. The latter is so designated
because it was independently derived (by this current study) and subsequently found to overlap with the region previously identified in 3 previous
studies as associated with lung cancer risk.
doi:10.1371/journal.pone.0031975.g001
Table 1. Covariate-adjusted significant (p,0.01) common tracts of homozygosity (cTOHs) over- or under-represented in lung
cancer cases compared to controls.
cTOH region # Chromosome region Start rs # End rs # Length # of SNPs P-value
1 FDR q-value OR
2 (95%CI)
1* 1 p13.2 rs773610 rs4307568 864192 149 0.005 0.193 0.193 0.28 (0.12,0.69)
2* 1 p12 rs861153 rs10802112 1967456 313 0.005 0.193 0.193 1.99 (1.23,3.21)
3* 2 p16.3–16.1 rs733726 rs4672095 7302499 1789 0.001 0.076 0.076 0.69 (0.55,0.85)
4 3 p24.2–24.1 rs4858125 rs13066666 3081499 606 0.003 0.204 0.204 1.75 (1.21,2.52)
5* 5 p15.31 rs10040610 rs13173919 1565397 412 0.004 0.204 0.058 0.40 (0.22,0.74)
6 6 p22.3–22.2 rs6937402 rs7775425 1179898 310 0.006 0.312 0.215 0.51 (0.32,0.82)
7 9 p22.3 rs10511606 rs10962339 1101955 263 0.007 0.35 0.343 2.06 (1.22,3.49)
Pvalue
1: p-value (obtained by a Wald test) of the effect of a cTOH region after adjusting for age, sex and smoking status in a logistic model.
OR
2 (95%CI): Adjusted odds ratio (OR), with its 95% confidence interval, of the cTOH region associated with lung-cancer cases over controls.
*: regions containing genes differentially expressed in lung cancer (AC) versus normal lungs (see Figure 4).
rs #: SNP identification numbers.
doi:10.1371/journal.pone.0031975.t001
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and Figure 1; see Discussion).
We particularly examined association of the TOHs harboring
these 9 genes and smoking status. Relatedly, the 9 differentially
expressed genes within the 6 cTOH/aTOH are germane in ever-
smokers compared to 3 that are germane in both ever- and never-
smokers [(p,0.0001), Table 3]. One important exception is
SBTBN1 and RTN4 within cTOH3/aTOH1 (2p16.3–16.1), where
over-expression occurs almost exclusively in controls relative to
lung-cancer cases, irrespective of smoking status (OR=0.000 and
0.08, p,0.0001; Table 3, Figures 2A and 4). ACYP2 (OR=0.08,
p,0.0001), also within this TOH, is under-expressed in ever-
smokers associated with decreased lung-cancer-risk, but its
differential expression is not germane in never-smokers (Table 3,
Figures 2A and 4). Overall, unique differential expression
signatures were observed for gene groups within a/cTOHs as
shown in Table 3 and Figure 4. Analysis of expression profiles of
genes in other aTOHs, eg, CD36 in aTOH4 (7q21.11), showed
under-expression in cases amongst ever-smokers (p,0.0001;
Table 3 and Figure 2B).
Expression profiles of the genes located in other significant
cTOHs, cTOH1, 2, 5 and 7 (1 p13.2, 1p12, 5p15.31 and 9p22.3,
respectively; Table 1) were analyzed. OLFML3 (1p12; Figure 3A),
was under-expressed in ever-smoking cases compared to never-
smoking cases consistent with a reduced risk as portrayed by
OR’s,1 (Table 3 and Figure 4). In contrast WDR3 (on 1p12;
Figure 3B) showed significant relative over-expression irrespective
of the smoking status, consistent with the TOH-relevant OR.1
(Table 3 and Figure 4). FASTKD3 (on 5p15.31; Figure 3C) showed
significant relative over-expression in ever-smoking lung-cancer
cases compared to never-smoking cases, consistent with the TOH-
relevant OR.1 (Table 3 and Figure 4). PSIP1 (on 9p22.3;
Figure 3D) was significantly under-expressed in both ever- and
never-smoking cases, OR,1 (Table 3 and Figure 4). In general,
we observed unique and similar expressional signatures for specific
gene-sets (Table 3, Figure 4). For example, we observed net under-
expression of a gene set within the cTOH3 in lung cancer cases
who are smokers (OR,1) [Table 3, Figure 4].
Discussion
Identifying risk factors, whether genetic or environmental, for
malignancies, including lung cancer, is a start for early diagnosis,
and tailoring heightened surveillance and prevention. The
common variant-common cancer hypothesis prevalent in the last
decade led to GWAS yielding common SNPs within 15q25, 5p15,
and 6p21 associated with lung cancer [5–10], accounting for ,3%
of all lung cancers. Based on the working hypothesis that other
genomic factors predisposing to or lowering lung cancer risk must
exist, we performed a genome-wide case-control analysis for long
TOHs, each of which harbors one to several lung-cancer-
predisposing or protective loci (most likely of low to moderate
penetrance). We identified 7 cTOHs and 5 aTOHs that are
significantly over- or under-represented in lung cancer cases versus
controls, after adjusting for age, gender and smoking status.
Interestingly, we found specific cTOH/aTOHs associated with
cases over controls independent of these covariates, with others
dependent on smoking status.
Importantly, our identified significant cTOH and aTOH
regions have been functionally validated by integrating differential
expression of specific genes residing in these critical intervals,
previously shown to play at least a somatic role in sporadic human
lung carcinomas, in murine models and/or participate in
neoplasia-associated signaling pathways (Table S4). We believe
that agnostically searching for cTOH and aTOH and then
integrating with expression data are powerful methods for finding,
and at the same time functionally genomically validating, new lung
cancer-risk regions and genes. Three previous lung cancer GWAS
studies have identified the 5p15 region to be associated with lung
cancer cases [4–10]. cTOH5 lies within 5p15.31 (our ‘‘candidate
Figure 2. cTOH3/aTOH1 and aTOH4 regions under-represented in lung cancer cases compared to controls. Single-SNP association
analysis was performed independently of TOH analysis and compared. The significant associations of single SNPs, and each TOH with lung cancer
cases versus controls, and their respective 95% CI (colored dashed lines), are shown. Below each of the lower panels are candidate gene names (multi-
colored) which were prioritized after testing for association between lung cancers and differential expression of each of the genes within and +/2
250 kb of the TOH, stratified by smoking status (p,0.0001; see Methods section). A. cTOH3/aTOH1 region (2 p16.3–16.1; brown line) significantly
under-represented in lung cancer cases and GWAS-identified SNPs (purple dots) in the same region (top panel) with their respective corresponding
risks as odds ratios (lower panel). B. aTOH4 (7q21.11; brown line) significantly under-represented in lung cancer cases and GWAS-identified SNPs
(purple dots) in the region (top panel) with their corresponding lung-cancer risks as odds ratios (OR; lower panel).
doi:10.1371/journal.pone.0031975.g002
Tracts of Homozygosity and Lung Cancer Risk
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represented in ever-smoking lung cancer cases and 3-fold in never-
smoking lung cancer cases. This serves as a strong positive control.
We have also identified a new candidate gene FASTKD3, beyond
those previously postulated, by integration of expression with
significant TOH in this region (Table S4).
We found only one TOH region where a significant aTOH lies
within its parent cTOH: aTOH 1 (2p16.3–16.1) and its parent
cTOH3, whose presence appears to confer a protective effect
against lung cancer in ever-smoking cases (OR,0.7, ie, over-
represented in controls versus cases; Tables 1 and 2). Differential
expression of a group of genes in this region seems to be equally
protective against lung cancer irrespective of smoking status or
history (Table 3, Figure 4). Eg, SPTBN1 codes for a beta-spectrim
which plays a role in decreasing cell surface recruitment of CD45
and CD3, and abrogating T-cell function [33]. Accordingly,
increased SPTBN1 expression (and over-representation of
aTOH1/cTOH3 in controls over cases) could plausibly protect
against lung cancer by increasing immune surveillance, given that
we know that smoking suppresses the CD4/CD8 T cell ratio [34].
While there is plausible existing evidence that under-expression of
genes within cTOH3/aTOH1 (Table 3, Table S4, Figure 4)
would be protective through various mechanisms [35], we do not
know what undiscovered mechanisms result in further mitigation
of smoking-associated lung-cancer risk. Unlike the other genes in
aTOH1/cTOH3, MTIF2 over-expression is associated with its
TOH differentially associated with cases and controls. MTIF2 is a
mitochondrial translation-initiation factor that partners with
RNaseL. In vitro over-expression of MTIF2 stabilizes mitochon-
drial RNA, inhibits apoptosis induced by interferon-alpha and
partially reverses alpha-interferon-cell growth inhibition [36].
Thus, this mechanism lends plausibility to the high OR in lung
cancer cases over controls and in ever-smoking cases over never-
smoking cases (OR=18.75 vs 8.25; Table 3, Table S4, Figure 4).
Amongst the other ‘‘most plausible’’ risk genes worthy of mention
are CD36 (aTOH4) and PSIP1 (cTOH7), both of which have
Figure 3. Lung cancer-associated cTOH1, cTOH2, cTOH5 and cTOH7 regions Single SNP association analysis was performed
(independently of TOH analysis), after which the SNP association was compared to significant TOHs obtained with TOH analysis.
The significant lung cancer-associated single SNPs, and TOH’s namely cTOH1, cTOH2, cTOH5, and cTOH7, and their respective 95% CI are shown. The
significant lung cancer association of aTOHs and SNPs in the region (top panel) and corresponding risk as odds ratios (lower panel) are shown in
panels A–D. Below the lower panels are candidate genes which were prioritized after testing for association between lung cancer and differential
expression of each of the genes within each significant TOH +/2250 kb TOH, stratified by smoking status (at p,0.0001; see Methods section).
doi:10.1371/journal.pone.0031975.g003
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alterations (especially in the oncogene PSIP1) may well lead to
NSCLC development (detailed in Table S4). Major vault protein
(MVP), implicated in the regulation of cellular signaling cascades
and multidrug resistance, has been shown to interact with
IFNgamma-regulated gene (CD36) in the H65 lung cancer cell
model [37]. Hence CD36, may be important in the development
of lung cancer. OLFM (cTOH1) and WDR3 (cTOH2) have been
implicated in apoptosis and cell cycle regulation in cancer cells
(Table S4). The two genes may be important in the regulation of
lung carcinoma cell proliferation.
In this study, differences in expression profiles displayed by
genes within significant TOH regions can be interpreted as due to
intra-c/aTOH or inter-c/aTOH composition and cross-talk,
together with environmental influences (Table 3, Figures 2 and
3). These genes likely work in conjunction with each other to either
Figure 4. Clustering of gene expression profiles for genes residing within significant c/aTOH +/2250 kb regions. Bi-clustering of
relative gene expression (horizontal) classified by ‘‘LC (tumor)+smoking status’’ and ‘‘normals+smoking status’’ (vertical). The acquisition, re-
standardization and merging of expression array data with TOH regions are detailed in the Methods section. Red coloration on the heat map is
relative over-expression of the genes, blue denotes relative under-expression and white no distinct relative expressional difference observed. The
heat map represents the differential expression profiles of 47 genes that were selected after univariate analysis (see Methods section for details). The
expression profiles of genes residing within and in proximity to the c/aTOH regions that are associated with tobacco use differentiate lung
carcinomas from normal lung tissue.
doi:10.1371/journal.pone.0031975.g004
Table 2. Covariate-adjusted significant (p,0.01) allelically-matched tracts of homozygosity (aTOHs) over- or under-represented in
lung cancer cases compared to controls.
Chromosome
region
cTOH &
its aTOH Start rs # End rs # Length
# of
SNPs
N(%)
Cases
N(%)
Controls P-value
1 FDR q-value OR
2 (95% CI)
2p16.3–16.1* cTOH region rs733726 rs4672095 7302499 1789 31(3.9)) 55(6.6) 0.001 0.076 0.076 0.69 (0.55,0.85)
2p16.3–16.1* aTOH1 rs2215911 rs4672095 7264821 1774 31(3.9)) 55(6.6) 0.005 0.600 0.600 0.50 (0.31,0.81)
3p25.3 cTOH region rs6804473 rs9990174 980014 316 28(3.6) 8(1.0) 0.055 0.737 0.737 1.65 (0.99,2.74)
3p25.3 aTOH2 rs6804473 rs9990174 980014 316 28(3.6) 8(1.0) 0.001 0.091 0.091 3.97 (1.75,8.99)
5q11.2–12.1* cTOH region rs1363793 rs410850 4097344 835 5(0.6) 22(2.7) 0.021 0.391 0.111 0.73 (0.55,0.95)
5q11.2–12.1* aTOH3 rs1363793 rs379212 4067496 820 5(0.6) 22(2.7) 0.004 0.213 0.207 0.23 (0.08,0.63)
7q21.11* cTOH region rs2018955 rs16886849 2708287 696 25(3.2) 9(1.1) 0.250 0.731 0.731 1.27 (0.85,1.89)
7q21.11* aTOH4 rs38094 rs16886849 2124458 413 25(3.2) 9(1.1) 0.008 0.680 0.594 2.95 (1.33,6.58)
13q31.1–31.3* cTOH region rs1361540 rs9524302 15043999 2438 14(1.8) 31(3.7) 0.377 0.643 0.628 0.91 (0.73,1.13)
13q31.1–31.3* aTOH5 rs370787 rs9584099 13011025 2046 14(1.8) 31(3.7) 0.006 0.342 0.244 0.39 (0.20,0.76)
Pvalue
1: p-value obtained by Wald test of the effect of the aTOH region after adjusting for age, sex and smoking status in a logistic model.
OR
2 (95%CI): Adjusted odds ratio (OR) with its 95% confidence interval of the aTOH region.
*:regionscontaining genesdifferentiallyexpressedinlungcarcinomas(mainlyAC)versusnormallung(seeFigure3)derivedfromexperimentallyvalidatedexpressionarrays.
doi:10.1371/journal.pone.0031975.t002
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presence or absence of tobacco (Tables 1, 2 and 3). A gene set
effect (intra-gene-gene signature) within a TOH is most likely
controlled by the direction of the OR and whether the genes are
over- or under-expressed. Eg, cTOH3 with OR,0.7 will most
likely have a gene-set that in combination relays a net protective
effect in lung cancer cases who are exposed to tobacco (Tables 1, 2
and 3).
Systematically integrating differential expression of specific
genes residing in critical intervals such as tracts of homozygosity,
have revealed new candidate lung cancer-risk-genes, as well as
genes previously shown to play a somatic role in sporadic human
lung carcinomas, in murine models and/or participate in
neoplasia-associated signaling pathways. This regional approach
of systems integration with identification of regional subsets of
genes can complement classical analyses which only consider
single genes represented by GWAS-associated SNP-risk.
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